Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

2.880 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 2.880
Bid (Size) 2.600 (2)
Ask (Size) 3.500 (1)
Prev. Close 2.880
Today's Range 2.880 - 2.880
52wk Range 0.1131 - 23.80
Shares Outstanding 198,742,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ALLARITY THERAPEUTICS, INC. ANNOUNCEMENT: If You Have Suffered Losses in Allarity Therapeutics, Inc. (NASDAQ: ALLR), You Are to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
-73.49%
-73.49%
1 Month
+1830.29%
+1830.29%
3 Month
+515.65%
+515.65%
6 Month
-58.86%
-58.86%
1 Year
-85.88%
-85.88%

More News

Read More
ALLR Stock Earnings: Allarity Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALLR
From Rosen Law Firm
Via Business Wire
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Are Chinese EV Stocks NIO, LI, XPEV Down Today?
Via InvestorPlace
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split
Via InvestorPlace
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Allarity Therapeutics Hit By SEC Notice Related Disclosures Of Once Lead Cancer Program
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.